{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:08:12Z","timestamp":1789765692099,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.bcmd.2011.03.007","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T16:04:54Z","timestamp":1304265894000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications"],"prefix":"10.1016","volume":"47","author":[{"given":"Kallistheni","family":"Farmaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Tzoumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2011.03.007_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05544.x","article-title":"Pathogenesis and management of iron toxicity in thalassemia","volume":"1202","author":"Hershko","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators, for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bcmd.2011.03.007_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","article-title":"Combined therapy with deferiprone and desferrioxamine","volume":"103","author":"Wonke","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.bcmd.2011.03.007_bb0020","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3324\/haematol.2009.009118","article-title":"Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone","volume":"94","author":"Telfer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2011.03.007_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0030","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcmd.2011.03.007_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2010.05.002","article-title":"Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone","volume":"156","author":"Evans","year":"2010","journal-title":"Transl. Res."},{"issue":"12","key":"10.1016\/j.bcmd.2011.03.007_bb0040","first-page":"1423","article-title":"Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion","volume":"88","author":"Kattamis","year":"2003","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bcmd.2011.03.007_bb0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0050","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V97.4.1115","article-title":"ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture","volume":"97","author":"Hershko","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcmd.2011.03.007_bb0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MPH.0b013e3181e015b0","article-title":"Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2years","volume":"32","author":"Jetsrisuparb","year":"2010","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1749-6632.2010.05591.x","article-title":"Combined iron chelation therapy","volume":"1202","author":"Galanello","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bcmd.2011.03.007_bb0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ajh.21711","article-title":"Daily alternating deferasirox and deferiprone therapy for \u201chard-to-chelate\u201d beta-thalassemia major patients","volume":"85","author":"Balocco","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0070","article-title":"Combining two orally active iron chelators for thalassemia","volume":"10","author":"Berdoukas","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0075","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcmd.2011.03.007_bb0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/ehm.10.74","article-title":"Iron chelation in thalassemia: time to reconsider our comfort zones","volume":"4","author":"Berdoukas","year":"2011","journal-title":"Expert Rev. Hematol."},{"issue":"2\u20133","key":"10.1016\/j.bcmd.2011.03.007_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000243801","article-title":"Deferasirox (Exjade) for the treatment of iron overload","volume":"122","author":"Cappellini","year":"2009","journal-title":"Acta Haematol."},{"issue":"5","key":"10.1016\/j.bcmd.2011.03.007_bb0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","article-title":"Clinical application of deferasirox: practical patient management","volume":"83","author":"Vichinsky","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St Pierre","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.03.007_bb0100","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","article-title":"MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients","volume":"106","author":"Wood","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.03.007_bb0105","unstructured":"Novartis updated full prescribing information for Exjade (deferasirox), Feb 2010 and warnings, precautions and drug interactions sections of the U.S., 2010."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0110","unstructured":"www.ferriprox.com for healthcare professionals outside US, about ferriprox, expanded indications, SPC, 2009."},{"issue":"2 Suppl 1","key":"10.1016\/j.bcmd.2011.03.007_bb0115","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0120","first-page":"253","article-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"issue":"suppl","key":"10.1016\/j.bcmd.2011.03.007_bb0125","first-page":"37","article-title":"American Diabetes Association: classification of glucose metabolism abnormalities","volume":"28","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.bcmd.2011.03.007_bb0130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.hoc.2010.08.015","article-title":"Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies","volume":"24","author":"Porter","year":"2010","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.bcmd.2011.03.007_bb0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/03630260903213231","volume":"33","author":"Kolnagou","year":"2009","journal-title":"Hemoglobin"},{"issue":"Suppl 2","key":"10.1016\/j.bcmd.2011.03.007_bb0140","first-page":"259","article-title":"HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels","volume":"2","author":"Gamberini","year":"2004","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1749-6632.2010.05583.x","article-title":"Fertility potential in thalassemia major women: current findings and future diagnostic tools","volume":"1202","author":"Singer","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"15","key":"10.1016\/j.bcmd.2011.03.007_bb0150","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2165\/00003495-200767150-00007","article-title":"Deferasirox: a review of its use in the management of transfusional chronic iron overload","volume":"67","author":"Yang","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0155","first-page":"59","article-title":"Reversal of endocrinopathies in transfusional iron overload patients\u2014the next frontier in iron chelation","volume":"2","author":"Farmaki","year":"2010","journal-title":"EJCMO"},{"issue":"Suppl 2","key":"10.1016\/j.bcmd.2011.03.007_bb0160","first-page":"249","article-title":"Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF)","volume":"2","author":"De Sanctis","year":"2004","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"2","key":"10.1016\/j.bcmd.2011.03.007_bb0165","first-page":"642","article-title":"Endocrine complications in patients with thalassaemia major","volume":"5","author":"Toumba","year":"2007","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"9","key":"10.1016\/j.bcmd.2011.03.007_bb0170","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood-2005-02-0460","article-title":"Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells","volume":"106","author":"Glickstein","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcmd.2011.03.007_bb0175","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","article-title":"Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences","volume":"108","author":"Glickstein","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.03.007_bb0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1196\/annals.1345.018","article-title":"Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use","volume":"1054","author":"Porter","year":"2005","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bcmd.2011.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","article-title":"Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications","volume":"111","author":"Sohn","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcmd.2011.03.007_bb0190","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1600-0609.2008.01204.x","article-title":"Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia","volume":"82","author":"Daar","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0195","doi-asserted-by":"crossref","first-page":"C1383","DOI":"10.1152\/ajpcell.00054.2007","article-title":"Non-transferrin bound iron reaches mitochondria by a chelator inaccessible mechanism. Biological and clinical implications","volume":"293","author":"Shvartsman","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"2","key":"10.1016\/j.bcmd.2011.03.007_bb0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20070823","article-title":"Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy","volume":"409","author":"Devanur","year":"2008","journal-title":"Biochem. J."},{"issue":"9220","key":"10.1016\/j.bcmd.2011.03.007_bb0205","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2011.03.007_bb0210","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000089475","article-title":"Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine","volume":"115","author":"Anderson","year":"2006","journal-title":"Acta Haematol."},{"issue":"3","key":"10.1016\/j.bcmd.2011.03.007_bb0215","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bcmd.2011.03.007_bb0220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10976640600698155","article-title":"Myocardial iron loading in patients with thalassemia major on deferoxamine chelation","volume":"8","author":"Tanner","year":"2006","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"9332","key":"10.1016\/j.bcmd.2011.03.007_bb0225","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcmd.2011.03.007_bb0230","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2011.03.007_bb0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"12","key":"10.1016\/j.bcmd.2011.03.007_bb0240","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","article-title":"Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia","volume":"115","author":"Pennell","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2011.03.007_bb0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2010.031468","article-title":"Continued improvement in myocardial T2* over two years of deferasirox therapy in \u03b2-thalassemia major patients with cardiac iron overload","volume":"96","author":"Pennell","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bcmd.2011.03.007_bb0250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.21830","article-title":"Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial","volume":"85","author":"Wood","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00277-009-0838-z","article-title":"Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major","volume":"89","author":"Pathare","year":"2010","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0260","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11534480-000000000-00000","article-title":"Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI","volume":"30","author":"Ruffo","year":"2010","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.bcmd.2011.03.007_bb0265","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2010.036061","article-title":"Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major","volume":"96","author":"Musallam","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0270","first-page":"309","article-title":"Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload","volume":"8","author":"Kolnagou","year":"2010","journal-title":"Blood Transfus."},{"issue":"318","key":"10.1016\/j.bcmd.2011.03.007_bb0275","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM198803313181303","article-title":"Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion","volume":"1998","author":"Merkel","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcmd.2011.03.007_bb0280","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00431-007-0602-0","article-title":"Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy","volume":"167","author":"Jaruratanasirikul","year":"2008","journal-title":"Eur. J. Pediatr."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0285","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2006.06203.x","article-title":"Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major","volume":"134","author":"Farmaki","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2011.03.007_bb0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2006.06296.x","article-title":"Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major","volume":"135","author":"Christoforidis","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"Suppl 2","key":"10.1016\/j.bcmd.2011.03.007_bb0295","first-page":"285","article-title":"Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center","volume":"2","author":"Gamberini","year":"2004","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"19","key":"10.1016\/j.bcmd.2011.03.007_bb0300","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2009-06-225615","article-title":"Pancreatic iron loading predicts cardiac iron loading in thalassemia major","volume":"114","author":"Noetzli","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2011.03.007_bb0305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3324\/haematol.2010.034397","article-title":"In search of the optimal iron chelation therapy for patients with thalassemia major","volume":"96","author":"Berdoukas","year":"2011","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1016\/j.bcmd.2011.03.007_bb0310","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0268-960X(08)70007-9","article-title":"Long-term efficacy and safety of deferasirox","volume":"22","author":"Cappellini","year":"2008","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.bcmd.2011.03.007_bb0315","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007990802160834","article-title":"Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study","volume":"24","author":"Scalone","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.bcmd.2011.03.007_bb0320","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000313447","article-title":"Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-thalassemia: results from the ESCALATOR Trial","volume":"123","author":"Taher","year":"2010","journal-title":"Acta Haematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:17Z","timestamp":1761049697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979611000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1079979611000921"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.03.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}